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Health state utility data in Cystic Fibrosis: A systematic 
review 
 
Introduction: Cystic Fibrosis (CF) is life-limiting, hereditable condition, with the highest 
prevalence in Europe. CF treatments have led to improvements in clinical symptoms, 
disease management and slowing disease progression. However, little is known about 
the health state utility (HSU) benefits through interventions, reduction in adverse 
events or disease status. Although HSU data has contributed to existing health 
economic modelling studies, a lack of such data has been highlighted. This review 
aims to provide a summary of all HSU data and to highlight related research gaps. 
Methods: Online searches were performed in 5 databases. Studies were included if 
they met any of the following criteria: 1) Measured utility in CF individuals, 2) Mapped 
between patient reported outcomes (PROMS) and preference-based instruments (e.g. 
CFQ-R and SF-6D), 3) Economic evaluations on the management of CF which use 
utility data and 4) Any CF clinical trial that reported health utility as an outcome. 
Results: A total of 15 studies were reviewed. Of the 15 studies, 10 provided mean 
health utility for specific CF populations. The remaining 5 articles provided health state 
utility data which was broken down in some form by CF condition relevant interventions 
or health states and included lung transplantation, Pulmonary exacerbation (PEx) 
events and Forced expiratory volume in 1 second (FEV1). Conclusion: Current health 
state utility data in CF is limited. There is considerable scope for research into 
preference-based elicitation studies and mapping algorithms.  
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Introduction 
 
Cystic Fibrosis (CF) is a life-limiting condition in the United Kingdom (U.K.), with 
projected prevalence in 2025 of 14,400 individuals (1). A growth rate of more than 
50% compared to 2010 (1). The average annual cost per CF individual for treatment 
is €49,000, doubling to €76,0001 for those with CF receiving additional caregiver 
support (2). As a result, even though CF has a low incidence it results in substantial 
economic burden (2). 
Treatments received by CF individuals are leading to improvements in clinical 
outcomes (3-6). However, the decision for treatment provision by governing bodies 
like the National Institute for Health and Care Excellence (NICE) in the U.K. is based 
on the cost-effectiveness of the treatment (7). Health state utility (HSU) values play a 
central role in valuing health-related quality of life (HRQOL) to support economic 
evaluations and can be elicited through direct or indirect methods (8). Indirect methods 
utilise questionnaires, such as the EQ-5D, to determine perceived health states of 
those filling in the questionnaire (also known as instruments). Completion of the 
instrument across many domains such as mobility, pain and mental health etc. results 
in a score which is then matched up to a utility value. On the other hand, direct 
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methods such as time-trade off (TTO) and standard gamble (SG) present hypothetical 
scenarios which ultimately allows for health utility evaluation. Both these techniques 
generate utilities anchored at 0 (death) and 1 (full health) (8). Indirect measures are 
required or suggested for inclusion in economic evaluations in countries which include 
England, Wales, Spain, France, Finland, Poland, New Zealand and the Netherlands 
(9). Measures, particularly those generated through generic questionnaires, such as 
the EQ-5D (7) are required by regulatory bodies like NICE.   
In an ideal world, for a health economist all clinical trials conducted on healthcare 
interventions would include some form of preference-based measure (PBM) which can 
provide a health utility value. This does not happen often where generic PBMs such 
as the EQ-5D, are included for completion by participants. One way to obtain health 
utility values is through mapping (8).  ‘Mapping’ allows conversion of outcomes from 
one incomplete PBM, such as a patient report outcome measure (PROM), to a generic 
PBM which allow calculation of utility values (9), which can in turn be used for health 
economic modelling.  
We undertake a systematic review which aims to identify all studies that determine the 
health state utility in CF as well as studies that provide utility data for defined 
populations of CF individuals. The main goal is to inform future health economic 
models by clarifying what data is available. Additionally, we look to inform future work 
by highlighting gaps in the research related to health state utility values of CF 
individuals.   
Methodology  
This study follows the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) guidelines (10) for reporting systematic reviews.  
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Inclusion criteria 
 
Although it is not entirely possible to apply the PRISMA guidelines to a HSU systematic 
review (11), we have attempted to do so in order to define the boundaries of this 
review. We have selected a Population, Intervention, Comparator, Outcome and Study 
Design (PICOS) framework (12), this is presented in Table 1.  Although we are aware 
that the HSU may not be attached to a particular intervention. When we describe the 
intervention, we aim to describe the method of determining the HSU values.  
The utility values we seek pertain to individuals of any age with CF and health states 
associated with these individuals. Studies that reported utility weights gained through 
proxy are also included. Studies utilising rating scales such as the visual analogue 
score (VAS) were excluded as they are not considered utility values anchored by full 
health and death and also risk scaling biases such as the end of scale bias (13). 
Studies included in the review were assigned to 1 of 4 categories during the title and 
abstract screening process which included: 1) Measuring utility in CF individuals, 2) 
Mapped between patient reported outcomes (PROMS) and preference-based 
instruments (e.g. CFQ-R and SF-6D), 3) Economic evaluations on the management 
of CF which use utility data and 4) Any CF clinical trial that reported health utility as an 
outcome. Studies excluded from this review were placed in the following categories: 
5) Study describing psychometric properties of CF-related instruments, 6) a CF 
individual’s perception of treatment/disease, 7) Articles about CF but not relevant, 8) 
Non-CF study and lastly, 9) Book or Thesis.  
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Criteria Notes 
Population Health states of Individuals with or Valuations pertaining to CF  
Intervention 
(Method) 
Any preference elicitation technique in order to determine health utility 
(Excluding VAS if scales not anchored to full health and death) 
Comparator Any similar elicitation technique or nothing at all 
Outcome 
Utility-based weighting of different severities of CF such as forced 
expiratory volume in 1 second (FEV1) (mild, moderate and severe), Lung 
transplantation, PEx events, hospitalisation 
Study types 
Health related quality of life derived utility studies, clinical trials, and 
mapping studies 
Language English only 
Time Frame Any 
Exclusion Books, Editorials or Conference Abstracts 
Table 1: Inclusion criteria 
Search strategies 
 
Search strategies were designed in order to identify the appropriate original published 
studies for this review. Text words, phrases, synonyms and indexing terms were 
selected through the Medical subject heading (MeSH) thesaurus. Preselected search 
strategies were also utilised from a previous study (14). Appropriate changes were 
made to the designed search strategies in order to tailor them to different subject 
heading terms in alternative databases.  
Databases included for this review were: MEDLINE Ovid PubMed (PubMed + PubMed 
Central), PsycINFO, Web of Science, Cochrane Library (NHS EED only), Cumulative 
Index to Nursing and Allied Healthcare Literature (CINAHL). Google was also 
searched using key search terms, as the search algorithm for this database changes 
frequently, with the first 50 results reviewed for inclusion. No date restrictions were 
applied, although we restricted the language to English only. 
Forward citation searching was undertaken using the Web of Science (ISI) to find 
further evidence which could be incorporated. Additionally, the bibliography of articles 
(backward citation searching) selected for full text review were hand-searched for 
relevant literature. The last date for conducting searches in the databases was 16th 
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June 2017. Conference abstracts were excluded. Search strategies are available in 
the supplementary material.  
Study selection 
 
Two rounds of selection were carried out by two authors (B.M and A.B.) based on the 
inclusion criteria. Any disagreements were adjudicated by a third author (J.W.).  
Quality assessment of studies 
 
Qualities assessment of the health utility studies was not conducted as there is no 
agreed reporting standard for these types of studies.  
Results 
 
Search results and study selection 
 
A total of 2,474 articles were found through our electronic searches. This number was 
reduced to 1,664 after removing 810 duplicates. A further 1,433 were excluded at the 
title and abstract screening stage, leaving 231 articles. Of these, 201 were removed 
after full text review. Finally, a further 15 articles were excluded because they were 
conference abstracts, not written in English or presented visual analogue scores (VAS) 
only.  A total of 15 articles were included in this review and were processed for data 
extraction in Microsoft Excel by B.M and A.B. A PRISMA diagram is presented in 
Figure 1, to demonstrate the process of study selection.  
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Figure 1: PRISMA diagram: Adapted from Moher et al (10), showing the process of study selection. 
 
Initial Search: 
CINAHL 
Cochrane Library 
MEDLINE 
PsycINFO 
Web of Science 
Google 
N= 2,474 
INCLUDED 
N= 231 
INCLUDED 
After Full Text Screening: 
Utility measurement 
Mapping study 
Economic Evaluation 
Clinical Trial 
N= 30 
Title and Abstracts screened at First Stage 
N= 1,664 
INCLUDED 
For Full Systematic review 
N= 15 
Title and Abstract screening 
EXCLUDED 
N = 1,433 
EXCLUDED 
Review irrelevant: 
Psychometric study 
Patient perception study 
General CF study 
Non-CF study 
Book/Thesis 
N = 201 
EXCLUDED 
Conference Abstracts - 7 
Not English – 5 
VAS only- 3  
N = 15 
EXCLUDED 
Duplicates removed 
N= 810 
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Author Year Country Subjects  Type of study Sample size total 
Solem et al 2016 USA 
Patients (Adults) 12 +/> (Ivacaftor therapy in CF ptx with 
G551D mutation) 
HRQOL study 161 
Chevreul et al  2016 Multiple Patients (Adults and Children) (or Proxy/carer) and carers HRQOL study 920 
Iskrov et al  2015 Bulgaria Patients (Adults and Children) and carers HRQOL study 40 
Chevreul et al 2015 France Patients (Adults and Children) (or Proxy/carer) and carers HRQOL study 166 
Angelis et al 2015 UK 
Adults, Children and Caregiver (Adults, Children and 
Caregiver) 
HRQOL study 74 
Acaster et al 2015 USA Patients. (Adults) 18 + > Mapping study 401 
Bradley et al 2013 UK 
Patients (Adults) >16 years, +bacterial infection, + 
antibiotics medication 
HRQOL study 94 
Dewitt et al 2012 USA 
Patients with mild lung impairment (FEV1:75 or more) and 
carers 
Clinical trial 328 
Fitzgerald et al 2005 Australia Children, Adolescents and Adults (5-18 years) Clinical trial 50 
Yi et al 2003 USA 
Patients (8-12 years) (No patients who have had lung 
transplant) (no further mention of actual population 
group) 
HRQOL study 65 
Suri et al 2001 UK Children only Clinical trial 40 
Selvadurai et al 2001 Australia 
Patients (8-16 years), admitted to hospital for infective 
PEx 
HRQOL study 66 
Czyzewski et al 1994 USA 
Patients and carers (Children and Adolescents and 
Caregiver) 
HRQOL study 254 
Busschbach et 
al 
1994 Netherlands 
Patients (Adults)waiting for and having received and lung 
transplant 
HRQOL study 6 
Oreinstein et al 1990 USA 
CF individuals older than 10 years, positive for bacterial 
infection and treated with a new antibiotic (proxy: 
examiner) 
HRQOL study 28 
 
Table 2: Summary characteristics of included studies (by descending publication date) 
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Study Characteristics  
 
Table 2 summarises key study characteristics. Included studies were published from 
1990 onwards. The most recent publication was 2016, with more than 20% being 
conducted in 2015. The duration of the studies varied, with most studies undertaking 
only a cross-sectional measurement, some included longitudinal follow up, up to 5 
years. Studies were undertaken in many different countries in and outside of Europe, 
with one study (15) covering multiple countries which were part of the same BURQOL-
RD research network study. The most common countries were United States of 
America (USA) (6) and United Kingdom (U.K.) (3). Two were from Australia (16, 17).  
In Table 2, we have identified the type of study being undertaken and have categorised 
them. Studies focusing on determining HRQOL were categorised as HRQOL studies. 
Studies focusing on evaluating HRQOL in conjunction to an intervention were 
categorised as clinical trials. Finally, studies focusing on deriving utility values from 
one instrument based on outcomes from another were labelled as mapping studies.
The patients in the studies included children, adolescents and adults in different 
combinations such as adults and children, children only or adults only. In some cases, 
studies included caregivers (2, 15, 18-20), some of whom were also assessed for their 
health utility (2, 15, 18, 19).  
The total number of individuals covered in the studies in this review equated to 2,693 
CF individuals, with sample sizes ranging from 6 to 920 people. The largest sample 
came from a study looking at the HRQOL across multiple European countries, 
conducted as part of the BURQOL-RD research network study (18). The population 
age varied across studies, with the youngest mean age of the participant being 
approximately 9 years (20) and the oldest mean age being 30 years (21).  
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Completion of the questionnaires was undertaken with no proxy on 6 occasions (19, 
21-25). The remaining studies utilised proxies in some patient groups to complete the 
instruments (2, 15, 18, 26, 27). Dewitt et al (26) only utilised a proxy when people with 
CF were under a particular age, <14 years old. Two studies were ambiguous about 
how the questionnaires were completed (16, 17)  and one study interviewed the 
participants and subsequently allowed them to complete the questionnaire at home 
(20). Lastly, one study collected information through face -to- face interviews (28). 
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Table 3: Summary of utility data collection (by descending publication date) 
                                                 
2 EQ-5D 5L used but value set for conversion is for EQ-5D 3L 
Author Date 
Method of obtaining utilities Utility for health 
states 
Value set utilised Intervention 
Direct Utility Multi-attribute Mapping study Instrument/Technique 
Solem et al 2016   ✓   EQ-5D-3L  ✓ Dolan et al (29) Ivacaftor 
Chevreul et al 2016   ✓   
EQ-5D-5L (mapping to 
3L value set)  
x Multiple countries  - 
Iskrov et al 2015   ✓   EQ-5D-3L  x  Dolan et al (29) - 
Chevreul et al 2015   ✓   
EQ-5D-5L (mapping to 
3L value set)  
x Perneger et al (30) - 
Angelis et al 2015   ✓   
 EQ-5D-5L> EQ-5D-3L 
2+ VAS 
x 
Kind et al (31) & 
Dolan et al (29) 
- 
Acaster et al 2015   ✓ ✓ CFQ-R to EQ-5D-3L ✓ Dolan et al (29) - 
Bradley et al 2013   ✓   EQ-5D -3L  ✓ MVP Group (32) 
Pulmonary Exacerbations 
(PEx) 
Dewitt et al 2012   ✓   
Health Utilities index 
2/3 
x Unknown  
Chloride Channel 
Activator 
Fitzgerald et al 2005   ✓   Quality of Wellbeing x Unknown  rhDNase 
Yi et al 2004 ✓ ✓   
Time trade off, 
Standard gamble & 
Health Utilities Index 2 
✓ 
Unknown 
& Direct valuation  
- 
Suri et al 2001   ✓   Quality of Wellbeing x  Unknown rhDNase 
Selvadurai et 
al 
2001  ✓  Quality of Wellbeing x Unknown 
Aerobic vs Resistance 
training 
Busschbach et 
al 
1994 ✓     
Time trade off & 
Standard gamble 
✓ 
Unknown 
& Direct valuation  
Lung Transplantation 
Czyzewski et 
al 
1994   ✓   Quality of Wellbeing x Unknown - 
Oreinstein et al 1990  ✓  Quality of Wellbeing x Unknown Antibiotic (Abx) 
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Utility elicitation  
 
Table 3 provides a summary of utility collection procedures, value sets used and 
interventions considered.  
From the 15 studies evaluated in this review, 13 studies reported utility scores described 
by multi-attribute utility instruments (MAUI).  A combination of direct and indirect utility 
elicitation methods were used to derive utilities. The most common multi-attribute 
instrument used to derive utility was the EQ-5D (2, 15, 18, 19, 22, 23). This included 
different version of the EQ-5D, the 3L and 5L. Studies that utilised the EQ-5D-5L version 
of the instrument (2, 15, 18) mapped their results to the 3L instrument due to the lack of 
a value set at the time, which is what NICE recommends (7). This method of deriving 
utilities was followed by utility elicitation through the Quality of Well-being instrument 
(QWB) (16, 17, 20, 24, 27). Lastly, the Health Utilities Index (HUI), version 2 and 3 were 
used in two studies (26, 28). Direct elicitation via TTO and SG was used by two studies 
(25, 28).  
Converting HRQOL scores into utilities 
 
We aimed to identify the value sets that were used to convert the multi-attribute scores 
into utility values. The U.K. value set was based on a study the by Dolan et al (29) was 
commonly used to calculate utility values for studies using the EQ-5D-3L instrument, 
although it was not used exclusively for U.K. studies. Only on two other occasions were 
different value set utilised for the EQ-5D-3L, by Chevreul et al (15) who used a French 
value set (30) for a French study and by Chevreul et al (18) who utilised multiple value 
sets for different European countries. Chevreul et al (18) also applied value sets from 
 13 
different countries to the multi-attribute instrument scores in cases where value sets were 
not available for that particular country.  
Five studies were investigated to understand which value sets they had utilised to convert 
Quality of Wellbeing scores into utilities (16, 17, 20, 24, 27). There was no clear 
information about the value set in any study. However, we are aware that the utility scoring 
algorithm is available from the developers of the instrument (8).  
Finally, two studies utilised the HUI, versions 2 and 3 (26, 28). Neither study provided 
information around the value sets that were used to calculate their respective utilities.  
Mapping between instruments 
 
A single study was found in this review that undertook mapping from the Cystic Fibrosis 
Questionnaire- Revised (CFQ-R) disease specific multi-attribute instrument to the EQ-
5D-3L (21).  
Health State-derived utility 
 
Of the 15 studies included in this review, only 5 provided data which were broken down 
in some form by CF disease relevant interventions or health states. These included health 
states related to the following: lung transplantation (25), PEx events (22, 23) and FEV1 
(21, 28).  
 
Lung Transplantation 
 
Lung transplantation utility data were separated by type of transplantation, bilateral and 
also by the time-points prior to and after the transplant (25).  
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This study measured utility at three-time points for individuals with bilateral transplant. 
This included before, during and after the lung transplant where the utilities were 0.8, 0.4 
and 0.9, respectively (25).  
Pulmonary exacerbations 
 
PEx utility was separated by the following health states, PEx requiring/ not requiring 
hospitalisation and the time periods prior to and after the events (22) and mild/ moderate/ 
severe PEx (23). It is evident from the data that increasing severity of PE events 
decreases the EQ-5D utility index. Utility values were 0.85, 0.79 and 0.60 for No, mild 
and severe PEx events respectively (23). 
Utility derived by the time since PEx event start and finish was investigated by Solem et 
al (22) and was based on whether the individual required hospitalisation or not. For PEx 
events that required hospital admission, utility was the worst during the period during the 
build-up to a PEx event (0.76). Utility up to 8 weeks prior to PEx was much better (0.9) 
compared to time periods up to 8 weeks after the event (0.85). This relationship is not 
evident in the non-hospitalised PEx events group, for the EQ-5D utility index score, with 
the utility score being highest 1-4 weeks after the PEx.  
FEV1 
 
FEV1 utility data were separated either by three (21) or four categories (28) of severity. 
This included the conventional mild, moderate and severe categorisation. Yi et al (28) 
further separate them into the following, <40% predicted, 40%-59% predicted, 60%-79% 
predicted and >79% predicted FEV1. The studies undertook FEV1 evaluation using 
different approaches. Acaster et al (21) mapped the CFQ-R instrument to the EQ-5D 3L 
by 3 FEV1 severity levels.  Yi et al (28) used combination of a direct utility approach of 
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TTO and SG in addition to HUI2 instrument to determine utility and categorise FEV1 by 4 
severity levels.  
The calculated utility data in the Acaster et al (21) study shows a decrease in utility score 
with increasing severity according to the EQ-5D-3L (data not shown). This relationship is 
not so evident in some cases for Yi et al (28). For instance, the HUI2 utility index scores 
do not decrease with increasing severity. This is also evident in the SG utility data across 
the varying FEV1 severity, with utility for 40-59% FEV1 (0.96) being better than that of 
>79% FEV1 (0.92). A similar pattern is evident in the TTO utility data. 
Population based-utility 
 
Of the 15 studies included in this review, 10 provide mean utility for specific CF 
populations. The studies cover populations on the following treatment/intervention: 
rhDNase (16, 24), antibiotics (27), aerobic vs resistance training (17), education (20) and 
chloride channel activator (26). Four additional articles simply observed the mean utility 
of CF individuals across Europe (2, 15, 18, 19). These studies particularly focus on 
characterising change in utility pre and post intervention over time.  
Recombinant Human DNase (rhDNase) 
 
Recombinant Human DNase (rhDNase) was evaluated in two clinical trials (16, 24). Each 
study targeted different population groups, children only (24) or children and adults (16). 
Both studies utilised a multi-attribute instrument to obtain utility data, the Quality of 
Wellbeing instrument (QWB) Although, Suri et al (24) study did not provide utility data 
post treatment with rhDNase, only including a baseline QWB score of 0.61 for their CF 
study population.  
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Suri et al (24) evaluated two different rhDNase treatment regimens, once daily or 
alternative days of rhDNase against twice daily hypertonic saline. The QWB scores 
following the 12-week trial showed no significant difference between the treatment 
options.  
Fitzgerald et al (16) evaluated the impact of administering rhDNase before or after 
physiotherapy treatment as part of a clinical trial. The results showed significant difference 
in QWB between the two treatment periods, 0.778 vs 0.752 (p<0.05). But it is not clear in 
the article what period represents which treatment option.  
Chloride Channel Activator 
 
The impact of Denufosol, a chloride channel activator, on CF individuals with mild 
impairment in lung function was evaluated over 48-weeks in a clinical trial (26). The study 
utilised the HUI2/3 to evaluate the utility of treatment, but there were no significant 
changes in utility of the treatment period in either instrument.  
Aerobic vs Resistance training 
 
Selvadurai et al (17) looked to determine the impact of aerobic vs resistance training on 
QWB subsequent to a pulmonary infection. Significant changes (p<0.05) in quality of life 
were only seen in the aerobic training group. However, this is poorly presented and 
difficult to quantify. 
Education intervention 
 
A clinical education intervention was provided to children and adolescents in order to 
determine QWB derived utility (20). The interdependent respondent agreement between 
parent/caregiver and adolescent CF individual in terms of utility was evaluated. Utility 
scores were 0.79 and 0.76 for caregivers and adolescents respectively.  
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Antibiotics 
 
Quality of wellbeing was applied to CF individuals being treated for PEx with oral 
Ciprofloxacin (27). Change in QWB was scored in the patient sample subsequent to 
treatment and showed a mean change of 0.104 but the worse and best change in QWB 
were -0.201 and 0.209, respectively.  
 
Cohort studies 
 
Finally, four studies (2, 15, 18, 19) evaluate the health derived utility in a range of 
European countries as part of the BURQOL-RD Research Network. The overall 
population covered within the individual countries were based on the same criteria, CF 
patient centre or its equivalent in different countries and CF Trust registries. Three studies 
were in depth publications (2, 15, 19), whilst the remaining article was a summary of the 
before mentioned articles with many additional countries which were evaluated as part of 
the project (18). The countries included Germany, Hungary, Italy, Spain and Sweden.  
Evaluation of the individual published studies showed discrepancies in the data. Not all 
the data in Chevreul et al (18) matched those figures provided within either Chevreul et 
al (15), Angelis et al (2) or Iskrov et al (19). Further evaluation of the number of patients 
utilised to reflect the EQ-5D-3L utility index data showed for example in Angelis et al (2), 
that different population numbers were used to calculate the utility score, 37 vs 33, 
respectively. A similar case is evident in the other two publications (15, 19). 
Discussion 
 
Health economic modelling has become a key component of healthcare decision making 
and it’s use is recommended by NICE for technology appraisals (7). However, in order to 
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undertake health economic modelling, there needs to be sufficient data to populate the 
model which in turn should reflect disease progression (33). Previous models have 
highlighted a lack of health outcomes evidence to inform CF health economic models (14, 
34), particularly around the health outcomes data.  
Health state derived utility values were only available for 5 studies (21-23, 25, 28). They 
focused only on lung transplantation, PEx events and FEV1. These studies have 
substantial limitations in their application. The lung transplantation data presented covers 
only bilateral lung transplantation (25). The treatment sample in Busschbach et al (25) 
was small. Utilisation of health utility data derived from these CF individuals for health 
economic modelling should be undertaken with caution. Additionally, these CF individuals 
were hypothetically put into different lung transplantation health states and were 
described as overestimating their utility (25).  
PEx event data presented covered a 16 to 48-week (22, 23) and has limited application 
for this particular health state due to the nature of the populations and treatments being 
investigated. Solem et al (22) evaluated the impact of Ivacaftor on PEx events. Data from 
Bradley et al (23), examines health utility of those who are taking oral or inhaled 
antibiotics. So, utility values can only be applied in CF individuals taking those treatments. 
FEV1 derived health state utility was investigated in two articles (21, 28). Acaster et al 
(21) categorised FEV1 derived utility into three states: mild, moderate and severe, which 
was self-reported in a cohort of self-diagnosed CF individuals.  Yi et al (28) reported and 
categorised FEV1 derived utility into 4 states, the data produced from this study has been 
utilised to model an antibiotic treatment in CF (35). Due to unconventional nature of 
categorising the FEV1 severity into four categories, the model by McGirr et al (35) had to 
 19 
transform these values to fit a three-health state FEV1 severity model. Previous models 
in CF have generally utilised three FEV1 health states (34, 36, 37).  
A total of 10 studies evaluated health utility in a range of different CF populations. These 
studies provided mean values at cross sectional time points, every 12 weeks for up to a 
year and a half. The majority of the utility information was gathered using the EQ-5D 
(3L/5L). These studies are of particular interest as the EQ-5D is the reference case 
instrument recommended by NICE for use in all Health Technology Appraisals (HTA) (7). 
From the studies that evaluated health utility with the EQ-5D we can understand that the 
population samples in all three studies (2, 15, 19) are quite different as well as the 
possible application of the utility data obtained from the studies.  
As the first study to review the literature for information around health utility of particular 
health states in CF, we identified that there are few studies which focus their attention on 
deriving utility data for CF individuals for the health states that may be needed to model 
the cost-effectiveness of interventions for CF. Considering the improvements in CF 
mortality and morbidity over the last 50 years which are largely related to improvements 
in screening (38, 39)  and treatment of the condition (1, 40), this finding comes as a 
surprise. Especially since health economic models currently exist which look at the cost-
effectiveness of a range of interventions available to CF individuals (14, 34-37, 41, 42) . 
For this dearth of evidence to come to light at this time suggests that CF research around 
health utilities has been slow.  
Health state derived utility values found in this review have limited application due to the 
treatments being considered. Such studies do not allow for the generalisability of the 
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health utility data to CF patients as the studies have selectively picked certain CF 
individuals for inclusion into their clinical trials.   
Future work should look at health state utility elicitation, longitudinal health utility 
measurement and mapping studies.  Health state preference elicitation could focus on 
significant adverse events such as PEx, CF related diabetes (CFRD), CF related Liver 
disease (CFLD) and other life-long complications such as Distal Intestinal Obstruction 
Syndrome. Attempts should be made to measure utility as close to the event as possible. 
Similarly, health utility of adults with differing FEV1 could be assessed multiple times 
annually or collected on encounter of complications or adverse events.  Such longitudinal 
measurement will allow for more reflective health economic evaluation of interventions. 
Such studies of health utility using the EQ-5D would also allow research to address 
problems around ceiling effects of the instrument which have been mentioned in NICE 
appraisals of Orkambi (43) and the published literature (22). This in turn would provide 
evidence of the appropriateness of the EQ-5D as a health utility measure in CF.   
Research into health utility derived from the EQ-5D is appropriate as the first measure in 
the U.K. as it is considered the most appropriate measure by NICE (7).  When studies 
use different measures, other than the EQ-5D, to determine health utility this inherently 
prevents cross comparison against other instruments used in different studies. As we 
know from this study a number of different methods have been used to determine health 
utility, but what decides which measure is the best or most appropriate? Using a single 
instrument to measure health utility would prevent this problem from arising. Studies 
conducted in the past around the comparison of utility data obtained from different 
instruments showed that there was poor to moderate agreement between instruments. 
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These differences can subsequently impact the cost per quality-adjusted life year (QALY) 
ratio (8).  
Another avenue for health state preference elicitation data could be the CF Trust registry, 
who recently launched a study looking at quality of life (QOL) in CF adults (44, 45). 
Although further information on the instruments used needs to be ascertained.   
Evident from the review, there is only one study looking at mapping one PBM instrument 
to the generic EQ-5D (21). Currently many instruments exist which measure patient-
reported outcome measures (PROMs) which do not have an associated preference-
based scoring system, so do not allow for utility and subsequent (QALYs) measurement. 
Future mapping studies between PROMs and PBM could allow for better availability of 
utility and QALY data, which would prove useful for health economic modelling in CF. An 
added incentive to undertake such studies, especially in the U.K. could be the fact that 
NICE recommend undertaking mapping in the absence of EQ-5D data in clinical trials (7).  
Evaluation of the James Lind Alliance (JLA) for the top research priorities identified for 
CF showed QOL evaluation, particularly for the long term effects  of Cystic Fibrosis 
transmembrane receptors (CFTR) modulators, was suggested (46). This further 
emphasises what patients, clinicians, nurses and other healthcare staff consider to be 
priorities of research in CF. 
Limitation of this review 
 
This review only considered full text articles, abstracts identified in this review would have 
been useful additions as full text articles. A study by Giron et al (47) evaluated EQ-5D-3L 
derived utility in Spanish patients who had mild or moderate PEx events, L’abbe et al (48) 
evaluated HRQOL in CF lung transplantation patients and Yarlas et al (49) evaluated CF 
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HRQOL in CF individuals in Europe and United States (U.S.). These articles would prove 
useful additions to this review if/when a future update if available. A total of 5 studies were 
excluded from this review as they were in language other than English. Incorporation of 
these articles could have contributed towards to better understanding of general country 
and population specific utility.  
Conclusion 
 
This review aimed to determine the level of available utility information around CF, 
particularly related to various health states. The studies identified were cross-sectional 
with little application for longitudinal evaluations without the use of assumptions. Work on 
eliciting health state preferences particularly for FEV1, PEx events (by severity) and lung 
transplantation require further work, some areas more than others. However, new studies 
on health state utility data is warranted for CFRD, Liver disease (CFLD) and intestinal 
obstructive syndrome. Further research on identifying health state utility value data needs 
for decision modelling for CF treatment would also prove beneficial for the health 
economic modelling of CF related treatments in order to aid future decision making in CF.  
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